Efficacy of lenvatinib in treating thyroid cancer

References

• Hundahl SA, Fleming ID, Fremgen AM, et al. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [see comments]. Cancer. 1998 [cited 2013 Sep 9];83(12):2638–2648. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9874472.
   PubMed Web of Science ®Google Scholar
• Nixon IJ, Whitcher MM, Palmer FL, et al. The impact of distant metastases at presentation on prognosis in patients with differentiated carcinoma of the thyroid gland. Thyroid. 2012;22(9):884–889. doi:10.1089/thy.2011.0535.
   PubMed Web of Science ®Google Scholar
• Mihailovic J, Stefanovic L, Malesevic M. Differentiated thyroid carcinoma with distant metastases: probability of survival and its predicting factors. Cancer Biother Radiopharm. 2007;22(2):250–255. doi:10.1089/cbr.2006.313.
   PubMed Web of Science ®Google Scholar
• Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994 [cited 2013 Sep 9];97(5):418–428. Available from: http://www.ncbi.nlm.nih.gov/pubmed/7977430.
   PubMed Web of Science ®Google Scholar
• Ruegemer JJ, Hay ID, Bergstralh EJ, et al. Distant metastases in differentiated thyroid carcinoma: a multivariate analysis of prognostic variables. J Clin Endocrinol Metab. 1988;67(3):501–508. doi:10.1210/jcem-67-3-501.
   PubMed Web of Science ®Google Scholar
• Pacini F, Schlumberger M, Dralle H, et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol. 2006;154(6):787–803. doi:10.1530/eje.1.02158.
   PubMed Web of Science ®Google Scholar
• Jarząb B, Sporny S, Lange D, et al. [Diagnosis and treatment of thyroid cancer - Polish guidelines]. Endokrynol Pol, 61(5):518–568. [ cited 2013 Sep 9]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21049469.
   Google Scholar
• Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2015;26(1): thy.2015.0020. doi:10.1089/thy.2015.0020.
   Web of Science ®Google Scholar
• Durante C, Haddy N, Baudin E, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab. 2006;91(8):2892–2899. doi:10.1210/jc.2005-2838.
   PubMed Web of Science ®Google Scholar
• Schlumberger M, Brose M, Elisei R, et al. Definition and management of radioactive iodine-refractory differentiated thyroid cancer. Lancet Diabetes Endocrinol. 2014;2(5):356–358. doi:10.1016/S2213-8587(13)70215-8.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. Surveillance, epidemiology and, end results program [Internet]. [cited 2016 Apr 7]. Available from: http://seer.cancer.gov/statfacts/html/thyro.html.
   Google Scholar
• Jarzab M, Krajewska J. Ewolucja możliwości systemowego leczenia chorych na raka tarczycy. Oncolocy Clin Pract. 2015;11(specialIssue PTOK):32.
   Google Scholar
• Droz JP, Schlumberger M, Rougier P, et al. Chemotherapy in metastatic nonanaplastic thyroid cancer: experience at the Institut Gustave-Roussy. Tumori. 1990 [cited 2014 Jun 12];76(5):480–483. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2256195.
   PubMed Web of Science ®Google Scholar
• Matuszczyk A, Petersenn S, Bockisch A, et al. Chemotherapy with doxorubicin in progressive medullary and thyroid carcinoma of the follicular epithelium. Horm Metab Res. 2008;40(3):210–213. doi:10.1055/s-2008-1046781.
   PubMed Web of Science ®Google Scholar
• Spano J-P, Vano Y, Vignot S, et al. GEMOX regimen in the treatment of metastatic differentiated refractory thyroid carcinoma. Med Oncol. 2012;29(3):1421–1428. doi:10.1007/s12032-011-0070-2.
   PubMed Web of Science ®Google Scholar
• Haddad R, Lydiatt W, Ball D, et al. NCCN clinical practice guidelines in oncology. Thyroid Carcinoma 2015 [cited 2016 Jan 24]. Available from: http://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf.
   Google Scholar
• Ahmed M, Barbachano Y, Riddell A, et al. Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population. Eur J Endocrinol. 2011;165(2):315–322. doi:10.1530/EJE-11-0129.
   PubMed Web of Science ®Google Scholar
• Gupta-Abramson V, Troxel AB, Nellore A, et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol. 2008;26(29):4714–4719. doi:10.1200/JCO.2008.16.3279.
   PubMed Web of Science ®Google Scholar
• Kloos RT, Ringel MD, Knopp MV, et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol. 2009;27(10):1675–1684. doi:10.1200/JCO.2008.18.2717.
   PubMed Web of Science ®Google Scholar
• Cohen EEW, Rosen LS, Vokes EE, et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol. 2008;26(29):4708–4713. doi:10.1200/JCO.2007.15.9566.
   PubMed Web of Science ®Google Scholar
• Sherman SI, Wirth LJ, Droz J-P, et al. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med. 2008;359(1):31–42. doi:10.1056/NEJMoa075853.
   PubMed Web of Science ®Google Scholar
• Cabanillas ME, Schlumberger M, Jarzab B, et al. A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: a clinical outcomes and biomarker assessment. Cancer. 2015;121(16):2749–2756. doi:10.1002/cncr.29395.
   PubMed Web of Science ®Google Scholar
• Bible KC, Suman VJ, Molina JR, et al. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol. 2010;11(10):962–972. doi:10.1016/S1470-2045(10)70203-5.
   PubMed Web of Science ®Google Scholar
• Leboulleux S, Bastholt L, Krause T, et al. Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. Lancet Oncol. 2012;13(9):897–905. doi:10.1016/S1470-2045(12)70335-2.
   PubMed Web of Science ®Google Scholar
• Carr LL, Mankoff DA, Goulart BH, et al. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res. 2010;16(21):5260–5268. doi:10.1158/1078-0432.CCR-10-0994.
   PubMed Web of Science ®Google Scholar
• Brose MS, Nutting CM, Jarzab B, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet. 2014. doi:10.1016/S0140-6736(14)60421-9.
   Web of Science ®Google Scholar
• Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;372(7):621–630. doi:10.1056/NEJMoa1406470.
   PubMed Web of Science ®Google Scholar
• Matsui J, Funahashi Y, Uenaka T, et al. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res. 2008;14(17):5459–5465. doi:10.1158/1078-0432.CCR-07-5270.
   PubMed Web of Science ®Google Scholar
• Yamamoto Y, Matsui J, Matsushima T, et al. Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage. Vasc Cell. 2014;6:18. doi:10.1186/2045-824X-6-18.
   PubMedGoogle Scholar
• Glen H, Mason S, Patel H, et al. E7080, a multi-targeted tyrosine kinase inhibitor suppresses tumor cell migration and invasion. BMC Cancer. 2011;11:309. doi:10.1186/1471-2407-11-309.
   PubMed Web of Science ®Google Scholar
• Okamoto K, Kodama K, Takase K, et al. Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models. Cancer Lett. 2013;340(1):97–103. doi:10.1016/j.canlet.2013.07.007.
   PubMed Web of Science ®Google Scholar
• Cabanillas ME, Habra MA. Lenvatinib: role in thyroid cancer and other solid tumors. Cancer Treat Rev. 2015;42:47–55. doi:10.1016/j.ctrv.2015.11.003.
   PubMed Web of Science ®Google Scholar
• Salajegheh A, Smith RA, Kasem K, et al. Single nucleotide polymorphisms and mRNA expression of VEGF-A in papillary thyroid carcinoma: potential markers for aggressive phenotypes. Eur J Surg Oncol. 2011;37(1):93–99. doi:10.1016/j.ejso.2010.10.010.
   PubMed Web of Science ®Google Scholar
• Yu X-M, Lo C-Y, Chan W-F, et al. Increased expression of vascular endothelial growth factor C in papillary thyroid carcinoma correlates with cervical lymph node metastases. Clin Cancer Res. 2005;11(22):8063–8069. doi:10.1158/1078-0432.CCR-05-0646.
   PubMed Web of Science ®Google Scholar
• Yu X-M, Lo C-Y, Lam AK-Y, et al. The potential clinical relevance of serum vascular endothelial growth factor (VEGF) and VEGF-C in recurrent papillary thyroid carcinoma. Surgery. 2008;144(6):934–940; discussion 940–941. doi:10.1016/j.surg.2008.07.027.
   PubMed Web of Science ®Google Scholar
• Yu X-M, Lo C-Y, Lam AK-Y, et al. Serum vascular endothelial growth factor C correlates with lymph node metastases and high-risk tumor profiles in papillary thyroid carcinoma. Ann Surg. 2008;247(3):483–489. doi:10.1097/SLA.0b013e31815fa447.
   PubMed Web of Science ®Google Scholar
• Bunone G, Vigneri P, Mariani L, et al. Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features. Am J Pathol. 1999;155(6):1967–1976. doi:10.1016/S0002-9440(10)65515-0.
   PubMed Web of Science ®Google Scholar
• St Bernard R, Zheng L, Liu W, et al. Fibroblast growth factor receptors as molecular targets in thyroid carcinoma. Endocrinology. 2005;146(3):1145–1153. doi:10.1210/en.2004-1134.
   PubMed Web of Science ®Google Scholar
• Tohyama O, Matsui J, Kodama K, et al. Antitumor activity of lenvatinib (E7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models. J Thyroid Res. 2014;2014:1–13. doi:10.1155/2014/638747.
   Google Scholar
• Schlumberger M, Jarzab B, Cabanillas ME, et al. A phase II trial of the multitargeted tyrosine kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid cancer. Clin Cancer Res. 2016;22(1):44–53. doi:10.1158/1078-0432.CCR-15-1127.
   PubMed Web of Science ®Google Scholar
• Gerald D, Chintharlapalli S, Augustin HG, et al. Angiopoietin-2: an attractive target for improved antiangiogenic tumor therapy. Cancer Res. 2013;73(6):1649–1657. doi:10.1158/0008-5472.CAN-12-4697.
   PubMed Web of Science ®Google Scholar
• Rini BI, Atkins MB. Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol. 2009;10(10):992–1000. doi:10.1016/S1470-2045(09)70240-2.
   PubMed Web of Science ®Google Scholar
• Ball D, Sherman S, Jarzab B, et al. Lenvatinib treatment of advanced RAI-refractory differentiated thyroid cancer (DTC): cytokine and angiogenic factor (CAF) profiling in combination with tumor genetic analysis to identify markers associated with response. J Clin Oncol. 2012;30 Suppl:5518.
   Google Scholar
• Yamada K, Yamamoto N, Yamada Y, et al. Phase I dose-escalation study and biomarker analysis of E7080 in patients with advanced solid tumors. Clin Cancer Res. 2011;17(8):2528–2537. doi:10.1158/1078-0432.CCR-10-2638.
   PubMed Web of Science ®Google Scholar
• Vergote I, Ball D, Kudo M, et al. Prognostic and predictive role of circulating angiopoietin-2 in multiple solid tumors: an analysis of approximately 500 patients treated with lenvatinib across tumor types. J Clin Oncol. 2014;32(15(Suppl)):11061.
   Google Scholar
• Boss DS, Glen H, Beijnen JH, et al. A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours. Br J Cancer. 2012;106(10):1598–1604. doi:10.1038/bjc.2012.154.
   PubMed Web of Science ®Google Scholar
• Shumaker R, Aluri J, Fan J, et al. Evaluation of the effects of formulation and food on the pharmacokinetics of lenvatinib (E7080) in healthy volunteers. Int J Clin Pharmacol Ther. 2014;52(4):284–291. doi:10.5414/CP201937.
   PubMed Web of Science ®Google Scholar
• Sherman SI, Jarzab B, Cabanillas, et al. A phase II trial of the multitargeted kinase inhibitor E7080 in advanced radioiodine (RAI)-refractory differentiated thyroid cancer (DTC). J Clin Oncol. 2011;15-suppl:5503.
   Google Scholar
• Stjepanovic N, Capdevila J. Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib. Biologics. 2014;8:129–139. doi:10.2147/BTT.S39381.
   PubMedGoogle Scholar
• Molina AM, Hutson TE, Larkin J, et al. A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC). Cancer Chemother Pharmacol. 2014;73(1):181–189. doi:10.1007/s00280-013-2339-y.
   PubMed Web of Science ®Google Scholar
• Schlumberger M, Tahara M, Wirth LJ. Lenvatinib in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;372(19):1868. doi:10.1056/NEJMc1503150.
   PubMed Web of Science ®Google Scholar
• Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer. 2007;96(12):1788–1795. doi:10.1038/sj.bjc.6603813.
   PubMed Web of Science ®Google Scholar
• Zhang Z-F, Wang T, Liu L-H, et al. Risks of proteinuria associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a systematic review and meta-analysis. PLoS One. 2014;9(3):e90135. doi:10.1371/journal.pone.0090135.
   Web of Science ®Google Scholar
• Qi W-X, Shen Z, Tang L-N, Yao Y. Congestive heart failure risk in cancer patients treated with vascular endothelial growth factor tyrosine kinase inhibitors: a systematic review and meta-analysis of 36 clinical trials. Br J Clin Pharmacol. 2014;78(4):748–762. doi:10.1111/bcp.12387.
   PubMed Web of Science ®Google Scholar
• Qi W-X, Min D-L, Shen Z, et al. Risk of venous thromboembolic events associated with VEGFR-TKIs: a systematic review and meta-analysis. Int J Cancer. 2013;132(12):2967–2974. doi:10.1002/ijc.27979.
   PubMed Web of Science ®Google Scholar
• Krajewska J, Kukulska A, Jarzab B. Drug safety evaluation of lenvatinib for thyroid cancer. Expert Opin Drug Saf. 2015;14(12):1935–1943. doi:10.1517/14740338.2015.1102883.
   PubMed Web of Science ®Google Scholar
• Bible KC, Cote GJ, Demeure MJ, et al. Correlative studies in clinical trials: a position statement from the International Thyroid Oncology Group. J Clin Endocrinol Metab. 2015;100(12):4387–4395. doi:10.1210/jc.2015-2818.
   PubMed Web of Science ®Google Scholar